Skip to main content
Erschienen in: Digestive Diseases and Sciences 2/2012

01.02.2012 | Original Article

Prevention of Induced Colitis in Mice by the Ras Antagonist Farnesylthiosalicylic Acid

verfasst von: Tal Oron, Galit Elad-Sfadia, Roni Haklai, Elizabeta Aizman, Eli Brazowski, Yoel Kloog, Shimon Reif

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Ras proteins are crucial for cell differentiation and proliferation. Targeting Ras with farnesylthiosalicylic acid (FTS), a Ras antagonist, has been suggested as a therapeutic strategy in proliferative and inflammatory diseases.

Aims

To examine the role of Ras and the therapeutic potential of FTS in experimental colitis.

Methods

Colitis was induced in 26 mice by adding 2.5% dextran sodium sulfate to their drinking water for 7 days during which 12 study mice were treated with FTS and 14 control mice were given normal saline. Two additional controls included 10 naïve mice treated with FTS and 7 naïve non-treated mice. The animals were followed clinically and sacrificed after 7 days. Their colons were isolated for histological assessment and for measurement of myeloperoxidase activity (MPO), tumor necrosis factor-α(TNF-α), and interleukin-1β(Il-1β) levels. Ras and activated Ras expression was determined by immunoblotting assays. T cell populations in the colon and spleen were analyzed by flow-cytometry.

Results

FTS induced a 2.1-fold reduction in activated Ras levels (P < 0.004). FTS-treated mice had lower disease activity scores (3.9 ± 1.7 vs. 7.5 ± 2.3, P < 0.001), and lower levels of MPO activity (1.65 ± 0.6 vs. 2.6 ± 0.8 units/g, P < 0.007), Il-1β (2.4 ± 3.6 vs. 24.3 ± 17.5 pg/mg, P < 0.01) and TNF-α (0.63 ± 0.5 vs. 1.9 ± 1 pg/mg, P < 0.04). FTS increased regulatory T cell population in the spleen (1.9 ± 0.4-fold, P < 0.04), and decreased effector T cell populations in the colon and spleen by 24 ± 3% (P < 0.03) and 27 ± 1% (P < 0.02), respectively. FTS had no remarkable side effects.

Conclusions

Ras is involved in the inflammatory processes of induced colitis in mice and its inhibition by FTS ameliorates the severity of the inflammation.
Literatur
2.
Zurück zum Zitat Shanahn F. Inflammatory bowel disease: Immunodiagnostics, immunotheraputics, and ecotherapeutics. Gastroenterology. 2001;120:622–635.CrossRef Shanahn F. Inflammatory bowel disease: Immunodiagnostics, immunotheraputics, and ecotherapeutics. Gastroenterology. 2001;120:622–635.CrossRef
3.
Zurück zum Zitat Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology. 1998;115:182–205.PubMedCrossRef Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology. 1998;115:182–205.PubMedCrossRef
4.
Zurück zum Zitat Bokoch GM, Der CJ. Emerging concepts in the Ras superfamily of GTP-binding proteins. FASEB J. 1993;7:750–759.PubMed Bokoch GM, Der CJ. Emerging concepts in the Ras superfamily of GTP-binding proteins. FASEB J. 1993;7:750–759.PubMed
5.
Zurück zum Zitat Reuther GW, Der CJ. The Ras branch of small GTPases: Ras family members don’t fall far from the tree. Curr Opin Cell Biol. 2000;12:157–165.PubMedCrossRef Reuther GW, Der CJ. The Ras branch of small GTPases: Ras family members don’t fall far from the tree. Curr Opin Cell Biol. 2000;12:157–165.PubMedCrossRef
6.
Zurück zum Zitat Scheffzek K, Ahmadian MR, Kabsch W, et al. The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science. 1997;277:333–338.PubMedCrossRef Scheffzek K, Ahmadian MR, Kabsch W, et al. The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science. 1997;277:333–338.PubMedCrossRef
7.
Zurück zum Zitat Kafri M, Kloog Y, Korczyn AD, et al. Inhibition of Ras attenuates the course of experimental autoimmune neuritis. J Neuroimmunol. 2005;168:46–55.PubMedCrossRef Kafri M, Kloog Y, Korczyn AD, et al. Inhibition of Ras attenuates the course of experimental autoimmune neuritis. J Neuroimmunol. 2005;168:46–55.PubMedCrossRef
8.
Zurück zum Zitat Clarke HC, Kocher HM, Khwaja A, et al. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. J Am Soc Nephrol. 2003;14:848–854.PubMedCrossRef Clarke HC, Kocher HM, Khwaja A, et al. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. J Am Soc Nephrol. 2003;14:848–854.PubMedCrossRef
9.
Zurück zum Zitat Katzav A, Kloog Y, Korczyn AD, et al. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor FTS. Clin Exp Immunol. 2001;126:570–577.PubMedCrossRef Katzav A, Kloog Y, Korczyn AD, et al. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor FTS. Clin Exp Immunol. 2001;126:570–577.PubMedCrossRef
10.
Zurück zum Zitat Weijzen S, Velders MP, Kast WM. Modulation of the immune response and tumor growth by activated Ras. Leukemia. 1999;13:502–513.PubMedCrossRef Weijzen S, Velders MP, Kast WM. Modulation of the immune response and tumor growth by activated Ras. Leukemia. 1999;13:502–513.PubMedCrossRef
11.
Zurück zum Zitat Haklai R, Weisz MG, Elad G, et al. Dislodgment and accelerated degradation of Ras. Biochemistry. 1998;37:1306–1314. Haklai R, Weisz MG, Elad G, et al. Dislodgment and accelerated degradation of Ras. Biochemistry. 1998;37:1306–1314.
12.
Zurück zum Zitat Marom M, Haklai R, Ben-Baruch G, et al. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem. 1995;270:2263–2270. Marom M, Haklai R, Ben-Baruch G, et al. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem. 1995;270:2263–2270.
13.
Zurück zum Zitat Elad-Sfadia G, Haklai R, Ballan E, et al. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem. 2002;277:37169–37175.PubMedCrossRef Elad-Sfadia G, Haklai R, Ballan E, et al. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem. 2002;277:37169–37175.PubMedCrossRef
14.
Zurück zum Zitat Elad-Sfadia G, Haklai R, Balan E, et al. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase. J Biol Chem. 2004;279:34822–34930.CrossRef Elad-Sfadia G, Haklai R, Balan E, et al. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase. J Biol Chem. 2004;279:34822–34930.CrossRef
15.
Zurück zum Zitat Belanis L, Sarah J, Plowman SJ, et al. Galectin-1 is a novel structural component and a major regulator of H-Ras nanoclusters. Mol Biol Cell. 2008;19:1404–1414.PubMedCrossRef Belanis L, Sarah J, Plowman SJ, et al. Galectin-1 is a novel structural component and a major regulator of H-Ras nanoclusters. Mol Biol Cell. 2008;19:1404–1414.PubMedCrossRef
16.
Zurück zum Zitat Shalom-Feuerstein R, Levy R, Makovski V, et al. Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras. Biochim Biophys Acta. 2008;1783:985–993. Shalom-Feuerstein R, Levy R, Makovski V, et al. Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras. Biochim Biophys Acta. 2008;1783:985–993.
17.
Zurück zum Zitat Kloog Y, Cox AD. RAS inhibitors: potential for cancer therapeutics. Mol Med Today. 2000;6:398–402.PubMedCrossRef Kloog Y, Cox AD. RAS inhibitors: potential for cancer therapeutics. Mol Med Today. 2000;6:398–402.PubMedCrossRef
18.
Zurück zum Zitat Le DT, Shannon KM. Ras processing as a therapeutic target in hematologic malignancies. Curr Opin Hematol. 2002;9:308–315.PubMedCrossRef Le DT, Shannon KM. Ras processing as a therapeutic target in hematologic malignancies. Curr Opin Hematol. 2002;9:308–315.PubMedCrossRef
19.
Zurück zum Zitat Reif S, Aeed H, Shilo Y, et al. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J Hepatol. 2004;41:235–241.PubMedCrossRef Reif S, Aeed H, Shilo Y, et al. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J Hepatol. 2004;41:235–241.PubMedCrossRef
20.
Zurück zum Zitat Reif S, Weis B, Aeed H, et al. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats. J Hepatol. 1999;31:1053–1061.PubMedCrossRef Reif S, Weis B, Aeed H, et al. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats. J Hepatol. 1999;31:1053–1061.PubMedCrossRef
21.
Zurück zum Zitat Marciano D, Ben-Bar G, Marom M, et al. Farnesyl derivatives of rigid carboxylic acid-inhibitors of Ras dependent cell growth. J Med Chem. 1995;38:1267–1272.PubMedCrossRef Marciano D, Ben-Bar G, Marom M, et al. Farnesyl derivatives of rigid carboxylic acid-inhibitors of Ras dependent cell growth. J Med Chem. 1995;38:1267–1272.PubMedCrossRef
22.
Zurück zum Zitat Paz A, Haklai R, Elad G, et al. Galectin-1 binds H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene. 2000;20:471–474. Paz A, Haklai R, Elad G, et al. Galectin-1 binds H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene. 2000;20:471–474.
23.
Zurück zum Zitat Rachmilewitz D, Karmeli F, Takabayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology. 2002;122:1428–1441.PubMedCrossRef Rachmilewitz D, Karmeli F, Takabayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology. 2002;122:1428–1441.PubMedCrossRef
24.
Zurück zum Zitat Bradley PP, Priebat DA, Christensen RD, et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982;78:206–209.PubMedCrossRef Bradley PP, Priebat DA, Christensen RD, et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982;78:206–209.PubMedCrossRef
25.
Zurück zum Zitat Sharon P, Ligumsky M, Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978;75:638–640.PubMed Sharon P, Ligumsky M, Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978;75:638–640.PubMed
26.
Zurück zum Zitat Karussis D, Abramsky O, Grigoriadis N, et al. The Ras-pathway inhibitor S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis. J Neuroimmunol. 2000;120:1–9.CrossRef Karussis D, Abramsky O, Grigoriadis N, et al. The Ras-pathway inhibitor S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis. J Neuroimmunol. 2000;120:1–9.CrossRef
27.
Zurück zum Zitat Zvibel I, Bar-Zohar D, Kloog Y, et al. The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells. Dig Dis Sci. 2008;53:1048–1053.PubMedCrossRef Zvibel I, Bar-Zohar D, Kloog Y, et al. The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells. Dig Dis Sci. 2008;53:1048–1053.PubMedCrossRef
28.
Zurück zum Zitat Olivera JB, Biedere N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci USA. 2007;104:8953–8958.CrossRef Olivera JB, Biedere N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci USA. 2007;104:8953–8958.CrossRef
29.
Zurück zum Zitat Fields PE, Gajewski TF. Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation. Methods Mol Biol. 2000;134:307–317.PubMed Fields PE, Gajewski TF. Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation. Methods Mol Biol. 2000;134:307–317.PubMed
30.
Zurück zum Zitat Genot E, Cantrell DA. Ras regulation and function in lymphocytes. Curr Opin Immunol. 2000;12:289–294.PubMedCrossRef Genot E, Cantrell DA. Ras regulation and function in lymphocytes. Curr Opin Immunol. 2000;12:289–294.PubMedCrossRef
31.
Zurück zum Zitat Mor A, Keren G, Kloog Y, et al. N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells. Eur J Immunol. 2008;38:1493–1502.PubMedCrossRef Mor A, Keren G, Kloog Y, et al. N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells. Eur J Immunol. 2008;38:1493–1502.PubMedCrossRef
32.
Zurück zum Zitat Marks RE, Ho AW, Robbel C, et al. Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood. 2007;110:1982–1988.PubMedCrossRef Marks RE, Ho AW, Robbel C, et al. Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood. 2007;110:1982–1988.PubMedCrossRef
33.
Zurück zum Zitat Mor A, Kloog Y, Keren G, et al. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice. Eur J Pharmacol. 2009;616:301–305.PubMedCrossRef Mor A, Kloog Y, Keren G, et al. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice. Eur J Pharmacol. 2009;616:301–305.PubMedCrossRef
34.
Zurück zum Zitat Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126:520–528.PubMedCrossRef Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126:520–528.PubMedCrossRef
Metadaten
Titel
Prevention of Induced Colitis in Mice by the Ras Antagonist Farnesylthiosalicylic Acid
verfasst von
Tal Oron
Galit Elad-Sfadia
Roni Haklai
Elizabeta Aizman
Eli Brazowski
Yoel Kloog
Shimon Reif
Publikationsdatum
01.02.2012
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 2/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1880-y

Weitere Artikel der Ausgabe 2/2012

Digestive Diseases and Sciences 2/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.